• Cardiovascular Effectiveness of Empagliflozin vs. Glucagon-Like Peptide-1 Receptor Agonists or Liraglutide in the EMPRISE Study

  • Jun 16 2022
  • Duración: 1 m
  • Podcast

Cardiovascular Effectiveness of Empagliflozin vs. Glucagon-Like Peptide-1 Receptor Agonists or Liraglutide in the EMPRISE Study Por arte de portada

Cardiovascular Effectiveness of Empagliflozin vs. Glucagon-Like Peptide-1 Receptor Agonists or Liraglutide in the EMPRISE Study

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • Within the EMPRISE® monitoring program, the cardiovascular effectiveness of empagliflozin (EMPA) vs. glucagon-like peptide-1 receptor agonists (GLP1RA) or liraglutide were evaluated. The patients ≥18 years with type 2 diabetes initiating (i) EMPA vs. GLP1-RA or (ii) EMPA vs. liraglutide were identified. Primary outcomes were hospitalization for heart failure (HHF), myocardial infarction (MI), stroke, and all-cause mortality.

    Relative to GLP1RA, EMPA had a lower risk of hospitalization for heart failure, and a similar risk of myocardial infarction, stroke, and mortality. Patients with and without CVD had similar outcomes. Estimates from EMPA vs. liraglutide, both overall and across subgroups, were similar to those from GLP1 RA.

    When compared to GLP-1RA or liraglutide, EMPA was linked with a lower risk of hospitalization for heart failure but a similar risk of myocardial infarction, stroke, and death throughout the CVD spectrum in real-world patients.
    Más Menos
activate_primeday_promo_in_buybox_DT
Más Menos

Lo que los oyentes dicen sobre Cardiovascular Effectiveness of Empagliflozin vs. Glucagon-Like Peptide-1 Receptor Agonists or Liraglutide in the EMPRISE Study

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles